Position in AKTS
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$86,309,750
New position
Shares Held
4,824,469
first reported quarter
Ownership
8.73%
of shares outstanding
% of Portfolio
3.69%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Position in Biotechnology
Healthcare · as of Mar 31, 2026EcoR1 Capital, LLC holds $2,284,236,973 across 26 Biotechnology names. AKTS ranks #6 (3.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ZYME |
Zymeworks Inc.
|
22,970,388 | $575,178,515 | |
| 2 | ANAB |
Anaptysbio, Inc
|
7,880,094 | $437,030,013 | |
| 3 | JAZZ |
Jazz Pharmaceuticals plc
|
1,706,469 | $322,607,964 | |
| 4 | CNTA |
Centessa Pharmaceuticals plc
|
6,000,000 | $238,320,000 | |
| 5 | CRNX |
Crinetics Pharmaceuticals, Inc.
|
4,288,120 | $155,744,518 | |
| 6 | AKTS |
Aktis Oncology, Inc.
This page
|
4,824,469 | $86,309,750 | |
| 7 | ORIC |
Oric Pharmaceuticals, Inc.
|
6,728,116 | $85,245,229 | |
| 8 | CGON |
CG Oncology, Inc.
|
1,102,000 | $74,583,360 |
All Filings in AKTS
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $86,309,750 | 4,824,469 | Shares | Sole | 2026-05-15 | |
| 2026-01-12 | $104,932,200 | 4,824,469 | Shares | Sole | 2026-01-20 | |
| No filing history on record for this holder in this stock. | ||||||